Objective: To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D). Methods: A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes). Subgroup differences in treatment effects of liraglutide 3.0 mg were evaluated by testing the interaction between treatment group and baseline BMI subgroup. Results: Significantly greater weight loss (0-56 weeks) was observed with liraglutide 3.0 mg versus placebo in all patient groups while on treatment. There was no evidence that the weight-lowering effect of liraglutide 3.0 mg differed between BMI subgroups (interaction p > 0.05). Similarly, for most secondary endpoints significantly greater improvements were observed with liraglutide 3.0 mg versus placebo, with no indication treatment effects differing between subgroups. The safety profile of liraglutide 3.0 mg was broadly similar across BMI subgroups. Conclusion: This post-hoc analysis did not indicate any differences in the treatment effects, or safety profile, of liraglutide 3.0 mg for individuals with BMI 27 to <35 or ≥ 35 kg/m². Liraglutide 3.0 mg can therefore be considered for individuals with a BMI of ≥ 35 as well as for those with a BMI of 27 to <35 kg/m².
Introduction
Obesity (BMI ≥ 30 kg/m 2 ) is a global health issue, the prevalence of which has risen over the last three decades [1] . This increasing prevalence is of clinical concern as the risk of death is increased in individuals who have overweight/obesity [2, 3] .
The increasing prevalence of the higher obesity classes (class II (BMI ≥ 35 to 40 kg/m 2 ), III (BMI ≥ 40 to 50 kg/m 2 ), IV (BMI ≥ 50 to 60 kg/m 2 ), V ( ≥ 60 kg/m 2 )), and the associated risk of complications associated with these BMI classes are of clinical importance. In the US, the prevalence of higher obesity classes increased at the fastest rates between 2001 and 2010, with prevalence of class III obesity rising by 70% and classes IV and above by >70% [4] .
Meta-analyses of prospective studies indicate that individuals with a BMI of 35-40 kg/m 2 have higher rates of all-cause mortality than those with a BMI in the healthy range (n = 1.46 million, hazard ratio 1.88 (95% confidence interval (CI) 1.77-2.00) [2] ; n = 3,950,000, hazard ratio 1.94 (95% CI 1.87-2.01) [3] ). The prevalence of type 2 diabetes (T2D), gallbladder disease, coronary heart disease, and high blood pressure are all increased in people with overweight and obesity classes I, II and III, compared with subjects of normal weight [5] . Furthermore, a BMI above the healthy range (18.5 to ≤ 25 kg/m 2 ) translates into increased cost burdens, and it has been estimated that healthcare costs for the treatment of obesityrelated diseases and medicine costs increase by 4% and 7%, respectively, for every unit of BMI above normal [6] .
There are many weight management strategies, and current options include dietary therapy, physical activity, behavioral therapy, pharmacotherapy, and bariatric surgery (or combinations thereof). Intervention for individuals with a BMI ≥ 27 kg/m 2 with a concurrent comorbidity (including diabetes) and intensification of treatment in higher obesity classes, have been suggested [7] . Many professional bodies, e.g. the American Diabetes Association (ADA) [8] , the Canadian Medical Association (CMA) [9] , the European Association for the Study of Obesity (EASO) [10] , the American Heart Association (AHA)/American College of Cardiology (ACC)/The Obesity Society (TOS) [7] , and the UK National Institute for Health and Clinical Excellence (NICE) [11] , specify consideration of bariatric surgery for individuals with BMI > 35 kg/m 2 plus a weight-related comorbidity. Interventions vary in effectiveness, but, encouragingly, even modest (5-10%) weight loss is associated with clinically meaningful health benefits [12] . Lifestyle interventions can achieve weight loss of 4-7%, whereas a 15-50% reduction in body weight can occur with surgery (depending on procedure). A treatment gap exists, however, for individuals with overweight/obesity who do not respond sufficiently to lifestyle interventions and are unable to, or do not wish to, undergo bariatric surgery.
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight management (at a dose of 3.0 mg) in individuals with BMI ≥ 27 kg/m 2 plus at least one weightrelated comorbidity or in those with obesity (BMI ≥ 30 kg/m 2 ) [13] has achieved clinically relevant weight loss in individuals with overweight/obesity, both without and with T2D [14, 15] .
Given the limited choice of effective interventions available for the treatment of adults with overweight/obesity, a post-hoc analysis of two phase IIIa studies was performed to establish whether the weight-lowering efficacy of liraglutide persists in higher BMI subgroups. In this analysis, the efficacy and safety of liraglutide 3.0 mg were compared in individuals with a BMI 27 to <35 and ≥ 35 kg/m 2 (the BMI where surgery is considered in many national guidelines) in populations without and with T2D.
Material and Methods

Clinical Trials
Two clinical trials were included in this post-hoc analysis; both were phase III, 56-week, randomized, double-blind, placebo-controlled, multicenter trials that recruited adults ( ≥ 18 years) with either obesity (BMI ≥ 30.0 kg/m 2 ) or overweight (BMI ≥ 27.0 kg/m 2 ) plus at least one weight-related comorbidity. These trials were chosen from the Satiety and Clinical Adiposity: Liraglutide Evidence (SCALE) program [14] [15] [16] [17] because they were both of 1 year's duration and were similar in design. The trials have been described in full elsewhere, but key information is summarized below [14, 15] 
Data Analysis
The treatment effects of liraglutide across baseline BMI subgroups (27 to <35 vs. ≥ 35 kg/m 2 ) were evaluated by statistical testing of interaction between treatment group (liraglutide 3.0 mg; placebo) and baseline BMI subgroup. Efficacy endpoints were analyzed using data from the full analysis set (FAS; all randomized, exposed individuals, with at least one post-baseline assessment of any efficacy endpoint). Safety outcomes were described using data from the safety analysis set (SAS; all randomized, exposed individuals).
Continuous efficacy variables (change from baseline to week 56) were analyzed using an analysis of covariance (ANCOVA) model. Baseline values were included as covariates in the model, with treatment, baseline BMI subgroup, interaction between treatment and baseline BMI subgroup, country, and sex as fixed factors. For SCALE Obesity and Prediabetes, additional fixed factors included baseline prediabetes status, BMI strata at baseline, and interaction between baseline prediabetes status and BMI strata. For SCALE Diabetes, additional fixed factors were background T2D treatment, HbA 1c strata, and interaction between background T2D treatment and HbA 1c strata.
Achievement of categorical weight loss at week 56 ( ≥ 5%, >10% and >15% weight loss, when compared with baseline body weight) was analyzed using a logistic regression model. The same fixed factors as the ANCOVA model were used, with baseline fasting body weight as covariate.
For SCALE Diabetes, only liraglutide 3.0 mg and placebo data were included in the analyses; liraglutide 1.8 mg data were excluded (liraglutide 3.0 mg is the only approved dose for weight management).
For endpoints measured as continuous variables, missing data were imputed using the last observation carried forward (LOCF) method. For achievement of categorical weight loss ( ≥ 5%, >10%, and >15%), missing data were imputed using LOCF before dichotomization. Baseline demographic and safety outcomes are based on observed means/proportions. Unless otherwise stated, efficacy endpoints are presented as estimated means or proportions adjusted to the observed baseline distribution of the individuals included in the models for each BMI subgroup.
Uncommon events (e.g. pancreatitis and other hepatobiliary events) were not statistically analyzed due to the low number of events in both treatment groups. For pancreatitis, only event committee-adjudicated events are shown (safety data for all events, including non-adjudicated events, have been reported elsewhere [14, 15] ). Event adjudication was performed by an independent external committee of medical experts and was a blinded process.
Results
Baseline Demographics
In general, baseline demographics were similar across treatment arms and BMI subgroups ( table 1 ) . In SCALE Obesity and Prediabetes, more individuals with BMI ≥ 35 than 27 to <35 
Efficacy (Body Weight) Endpoints
Significantly greater weight loss was seen from baseline to 56 weeks on treatment with liraglutide 3.0 mg when compared with placebo in individuals without and with T2D ( fig. 1 a,b) . Analysis of the interaction between treatment effect and baseline BMI subgroup (27 to <35 and ≥ 35 kg/m 2 ) revealed no evidence that the effect of liraglutide 3.0 mg on body weight differed between the two baseline BMI subgroups (interaction p > 0.05; fig, 1 a, 2 ) .
Similarly, statistically significantly more individuals (without and with T2D) achieved ≥ 5%, 10%, and 15% categorical weight loss at week 56 with liraglutide 3.0 mg, than with placebo ( fig. 2 ) , with no evidence to suggest that the effect of liraglutide 3.0 mg on categorical weight loss achievement differed between the two baseline BMI subgroups (interaction p > 0.05). Estimated treatment differences between the treatment arms (liraglutide 3.0 mg vs. placebo) for continuous efficacy endpoints, and odds ratios (liraglutide 3.0 mg vs. placebo) for the achievement of categorical efficacy endpoints are stated in table 3 , with corresponding 95% CIs.
Efficacy (Non-Body Weight) Endpoints
For the majority of secondary endpoints, statistically significantly greater improvements were seen with liraglutide 3.0 mg versus placebo from baseline to 56 weeks in individuals without and with T2D (waist circumference ( fig.1 c) , HbA 1c ( fig. 1 d) , fasting plasma glucose ( fig. 1 e) , and blood pressure ( fig. 1 f) ). Furthermore, for the majority of secondary endpoints, analysis of the interaction between treatment group and BMI subgroup revealed no evidence that the effects of liraglutide 3.0 mg differed between the BMI subgroups (interaction p > 0.05, fig. 1 c-g ). However, for individuals without T2D, greater improvement relative to placebo in the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire score related to physical function was recorded for individuals with baseline BMI ≥ 35 kg/m 2 (interaction p value = 0.04; fig. 1 g) . The same trend was seen in individuals with T2D, with greater mean improvement in IWQOL-Lite physical function score under liraglutide 3.0 mg treatment compared with placebo occurring in the high BMI subgroup. However, this difference between BMI subgroups was not statistically significant (interaction p = 0.05; fig. 1 g) .
Statistically significantly greater reductions in HbA 1c and FPG were seen with liraglutide 3.0 mg than with placebo in individuals without and with T2D, with no evidence that the effect of liraglutide 3.0 mg treatment on glycemic reduction differed between the two baseline BMI subgroups (interaction p > 0.05; fig. 1 d,e) . Similarly, there was no evidence that the effect of liraglutide 3.0 mg treatment on blood pressure reduction differed between the two baseline BMI subgroups (interaction p > 0.05; fig. 1 f) .
Safety Outcomes
Overall, treatment-emergent adverse events (AEs) and treatment-emergent serious AEs were broadly similar across the BMI subgroups ( table 2 ). Rates of gallbladder disorders were low, but numerically higher with liraglutide 3.0 mg than with placebo, and the frequency of these outcomes was similar across BMI subgroups ( table 2 ) . No individuals with T2D experienced acute pancreatitis in either treatment group. The number of individuals without T2D experiencing adjudicated acute pancreatitis events was low, but numerically higher with liraglutide 3.0 mg than with placebo; the frequency of acute pancreatitis events in these individuals was similar across BMI subgroups ( table 2 ). The most frequently reported AEs were gastrointestinal (GI); rates of GI disorders were broadly similar across BMI subgroups, but higher with liraglutide 3.0 mg than with placebo ( table 2 ). The change in pulse observed with liraglutide 3.0 mg was similar across BMI subgroups. For individuals without T2D the mean pulse rate increased by 3.1 beats/min (bpm) (<35 kg/m 2 ) and 2.3 bpm ( ≥ 35 kg/m 2 ), with similar increases observed in individuals with T2D (2.3 and 1.7 bpm, respectively) ( table 2 ). A 2-3 bpm increase in heart rate associated with liraglutide 3.0 mg has been described previously [14, 15] ; however, the clinical significance of increases in heart rate occurring with GLP-1 receptor agonists is unknown [19] .
Overall withdrawal rates were lower with liraglutide 3.0 mg than with placebo in individuals without (n = 698/2,487 (28.1%) vs. n = 443/1,244 (35.6%)) and with T2D (n = 99/423 (23.4%) vs. n = 72/212 (34.0%)). More individuals withdrew from the trial due to AEs with liraglutide. For individuals with T2D, rates of withdrawals due to AEs were numerically higher in the low BMI than in the high BMI subgroup in both treatment arms ( table 2 ). 22 (13) 5 (5.6)
9 (12) 19 (8.2) 28 (13) 8 (6.5) 11 (10) Severe adverse events 26 (13.6) 35 (20) 11 (12.4) 17 (23) 26 (11.3) 48 (23) 10 (8.1) 13 (12) Adverse events leading to withdrawal 25 (13.1)
32 (19) 4 (4.5)
4 (5) 14 (6.1) 19 (9) 3 (2.4)
(3)
Gastrointestinal adverse events 184 (107) 11 (12.4) 24 (33) 52 (22.5) 145 (70) 16 ( In individuals with T2D, rates of documented symptomatic hypoglycemia were low, but higher with liraglutide 3.0 mg than with placebo in both BMI subgroups ( table 2 ). In the liraglutide 3.0 mg treatment arm of SCALE Diabetes, two individuals with baseline BMI 27 to <35 kg/m 2 , and one with BMI ≥ 35 kg/m 2 , experienced severe hypoglycemia, whereas no events were observed under placebo treatment.
Discussion
In individuals both without and with T2D, liraglutide 3.0 mg was effective and well tolerated, irrespective of BMI subgroup. There was no evidence that the weight-lowering effect of liraglutide 3.0 mg differed between BMI subgroups ( fig. 1 a,b, 2 ; tables 3 , 4 ) .
All individuals received a lifestyle (i.e. diet and exercise) intervention that included dietary advice from a qualified dietician, in line with AHA/ACC/TOS guidelines [7] . It has been reported that dietician-delivered counselling is more effective than physician-delivered outpatient programs, achieving ∼ 3-6 kg weight loss in individuals with overweight/obesity [20] . Weight loss was expected with placebo as a result of the robust diet and exercise intervention, so it was encouraging the estimated treatment difference between liraglutide and placebo indicated that the additional weight loss achieved with liraglutide was clinically relevant for individuals both without (-5.4% ( fig. 1 a, all individuals) ) and with T2D (-4.0% ( fig. 1 a, all individuals) ).
The magnitude of the body weight reductions achieved while on treatment with liraglutide 3.0 mg ranged between an estimated mean weight loss of 5.7% (BMI 27 to <35 kg/m 2 with T2D) and 8.2% (BMI 27 to 35 kg/m 2 without T2D) in the BMI subgroups analyzed ( table 3 ) . These reductions are likely to be clinically beneficial given compelling evidence that 5-10% weight loss is associated with improved glucose and lipid metabolism, lower incidence of T2D, improved psychosocial outcomes, and reductions in several other weightrelated comorbidities (hypertension, sleep apnea, osteoarthritis) [12, [21] [22] [23] [24] [25] .
The high BMI subgroup had greater absolute (kg) weight loss compared with the low BMI subgroup ( fig. 1 b) , but had a smaller proportional weight loss (% change from baseline) than the low BMI subgroup ( fig. 1 a) . This discrepancy reflects that in the high BMI subgroup, each additional kg of body weight loss corresponds to a smaller %-change than in the low BMI subgroup.
Previously published phase III data indicate that liraglutide 3.0 mg has a range of beneficial secondary effects, including improvements in glycemic endpoints, blood pressure and overall health-related quality of life in individuals without [14] and with [15] T2D. In the current analysis, for most endpoints there was no evidence to suggest that the effects of liraglutide 3.0 mg differed between BMI subgroups in individuals with or without T2D. The IWQOL-Lite Questionnaire Physical Function score improved more with liraglutide compared with placebo in the high BMI subgroups; however it is beyond the scope of this study to investigate this aspect further.
The overall safety profile of liraglutide 3.0 mg was broadly similar for both BMI subgroups. As reported elsewhere, the most common AEs associated with liraglutide were GI-related [14, 15] . GI side effects are common with the GLP-1RA drug class, mainly occurring transiently during dose escalation [26] . There is evidence for an exposure--response relationship between liraglutide and GI AEs (and a tendency for lower drug exposure in heavier individuals) [27] . However, rates of GI AEs were similar in both BMI subgroups. Similarly, rates of AEs of special interest (gallbladder disorders, adjudicated acute pancreatitis) were comparable across the BMI subgroups analyzed. 
Limitations
Limitations of this post-hoc analysis include the fact that neither SCALE Obesity and Prediabetes nor SCALE Diabetes was designed or powered for the detection of differences between subgroups and that tests for interaction between treatment group and baseline BMI subgroup have low power in this setting. Further, the tests for interaction between treatment group and baseline BMI subgroup were not adjusted for multiplicity.
Clinical Relevance
A treatment gap exists for individuals with overweight/obesity who do not respond sufficiently to lifestyle interventions and are unable to, or do not wish to, undergo bariatric surgery. Barriers to surgery can include regional variation in healthcare [28] , contraindications from comorbidities [29, 30] , cost [31] , and patient preference for nonsurgical interventions [32, 33] . The increased risks to health and detrimental effects on quality of life associated with BMI ≥ 35 kg/m 2 highlight the importance of finding additional treatment options for these high-risk individuals [5, 34] . Used appropriately, effective prescription drugs in combination with lifestyle interventions could help by filling this weight management treatment gap and provide additional treatment options for individuals for whom currently only few are available [35, 36] .
Conclusion
Previously published phase IIIa data have documented the weight-lowering effect of liraglutide 3.0 mg and an acceptable safety profile for weight management in individuals (without [14] and with [15] 
